Capital Markets Event: View a recording and access materials presented at OXB’s Capital Markets Event held on 2nd June 2026.

VectorXcellerator: OXB has selected the first programmes to move forward through VectorXcellerator, supporting earlier collaboration in advanced therapies.

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture.

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category.

Webinar: Driving down the cost- Optimising CGT with the right CDMO partner

Location: Virtual Start Date: 13th Nov, 2025
Details: 11:00 am EST / 5:00 pm CET

Driving down the cost: Optimising CGT with the right CDMO partner

Webinar with Endpoints News

What will you learn during this webinar?

  • The primary cost drivers in cell and gene therapy manufacturing
  • How a CDMO leveraged platform data to reach GMP faster in a case study
  • How CDMOs create value beyond capacity through expertise, innovation, and scale
  • How to evaluate and select the best CDMO partner to drive cost efficiency and long- term success

Speakers:
Mark Caswell, Site Head of UK Operations, OXB
Nick Clarkson, VP, Head of Process Development, OXB
Chris Gray, VP, Head of Manufacturing & MSAT, OXB